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The methodologist’s point of view
Rita Banzi  Lorenzo Moja  Ivan Moschetti 
Alessandro Liberati
A Cochrane systematic review explored the potential role
of rimonabant for overweight and obesity [1]. On the basis
of surrogate outcomes reported in the included RCTs,
rimonabant has been a candidate (by its producer) to act as
a pleiotropic agent for the entire cardiovascular risk spec-
trum. Is this compelling evidence to consider rimonabant
the new panacea for the ‘‘metabolic syndrome’’ or are we
facing another attempt of disease mongering by a new
market frontier?
Rimonabant has been shown to reduce food intake,
appetite and body weight in overweight or obese people.
Four randomized controlled trials (RIO-Europe [2], RIO-
North America [3], RIO-diabetes [4], RIO-lipids [5])
evaluated rimonabant 20 mg versus rimonabant 5 mg
versus placebo. All interventions were given over 1 year
and included the addition of a hypocaloric diet. All trials
were designed, conducted and reported with the contribu-
tion of Sanofi-Aventis drug company. The Cochrane
review (‘‘Rimonabant for overweight and obesity’’) [1]
includes evidence from these four trials.
Cochrane review
Overall 6,625 patients aged 18 and above, with a BMI
C 27 kg/m and with treated or untreated hypertension or
dyslipidaemia were enrolled. Specific inclusion criteria for
RIO-Diabetes and RIO-Lipids were uncontrolled type 2
diabetes and untreated dyslipidaemia, respectively. In all
trials the primary outcome was the change in weight from
baseline to 1 year post-treatment. Among secondary out-
comes, the prevalence of metabolic syndrome after 1 year
and the change in cardiometabolic risk factors, such as
blood pressure and lipid profile, were evaluated.
Compared to placebo, the meta-analysis of the included
studies showed a statistically significant weight reduction
with a mean of 4.64 kg after 1 year for rimonabant 20 mg,
while the pooled effect of rimonabant 5 mg was a weight
reduction of 1.25 kg after 1 year, resulting in a very limited
clinical effect. Improvement in waist circumference, high-
density lipoprotein cholesterol, trygliceride levels and
blood pressure were also observed with patients on rimo-
nabant 20 mg.
Patients treated with rimonabant 20 mg reported sig-
nificantly more serious adverse events (RR = 1.37, 95%
CI 1.04, 1.80) and greater rate of discontinuation due to
adverse effects (RR = 1.92, 95% CI 1.57, 2.34) than pla-
cebo. The main safety issues were adverse psychiatric
events, especially because patients with current depressions
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were excluded from the clinical trials. Even in this highly
selected population anxiety, mood disorders and depressive
symptoms were reported more frequently with rimonabant
20 mg in comparison to rimonabant 5 mg and placebo.
Cochrane review as drug company amplifier?
Individual studies included in this review were all spon-
sored by the producer of rimonabant; this could have led to
a conflict of interest which could have affected the results.
There is evidence that Pharma companies’ sponsored
studies tend to provide more often positive results and
overestimate treatment effects [6–8]. Publication and out-
come reporting biases cannot be ruled out, as preliminary
trials have probably been done but are not retrievable. The
high attrition rate (i.e. patient losses during the studies) in
both treatment and placebo groups (approximately 40% in
all studies), which is difficult to compensate by any form of
analysis, had lowered the quality of the studies. One could
have expected a more thorough critical appraisal of the
clinical relevance of the evidence from the Cochrane
reviewers; to avoid that meta-analysis could become an
amplifier of non-pertinent and irrelevant results, eventually
pushing the drug’s promotion.
Rimonabant in the context
As a general guideline, the US National Institutes of Health
(NIH) recommended that the initial goal of weight loss
therapy in overweight and obese patients should be to
reduce body weight by approximately 10% from baseline
[9]. Following this indication, both the European Medi-
cines Agency (EMEA) and the American Food and Drug
Administration (FDA) require any anti-obesity agent to
produce a weight loss of 10% of initial bodyweight com-
pared to placebo [10]. The use of rimonabant after 1 year
of treatment produces a modest weight loss of approxi-
mately 5%. Comparing this result with two other approved
anti-obesity drugs, orlistat and sibutramine, it could be
argued that the weight loss associated with rimonabant is
slightly greater than orlistat and comparable to sibutramine
[11]. These comparisons are indirect and readers should be
aware that there are often systematic differences between
the trials addressing one intervention and the trials
addressing the other, taking the results of these compari-
sons cautiously. In 2006 Rimonabant 20 mg film-coated
tablets had been approved, on the basis of the results of
these four RCTs, by the EMEA under the trade name
Acomplia. The approved indication is ‘‘as an adjunct to
diet and exercise for the treatment of obese patients
(BMI C 30 kg/m2) or overweight patients (BMI C 27 kg/
m2) with associated risk factor(s), such as type 2 diabetes
or ‘‘dyslipidaemia’’ [12].
The attempt to expand the market for rimonabant
Beyond weight management, the proposed indications by
the producer included treatment for type 2 diabetes,
dyslipidaemia, smoking cessation, and management of
multiple cardiometabolic risk factors in patients with
metabolic syndrome. Although rimonabant has shown
potential in the management of these conditions, the lack of
comparative data with standard therapies and/or the
uncertainties regarding the consistency and magnitude of
the effect (i.e. smoke cessation) were the bases for a neg-
ative benefit risk assessment by the EMEA. Although
relevant decreases in certain cardiac risk factors associated
with obesity have been seen with a loss of at least 5–10%
of initial weight, information regarding the effect of ri-
monabant on major cardiovascular events will only be
available when the results of the CRESCENDO trial, which
looks to these events in more than 17,000 patients treated
with rimonabant for 5 years, are finalized in a few years
[13].
An arbitrary and fluid outcome: the metabolic
syndrome
Within the EMEA regulatory process, the ‘‘metabolic syn-
drome indication’’ required a profound discussion by an ad-
hoc panel of experts, who agreed that metabolic syndrome
cannot be considered today as a target for therapy in itself,
but rather as an additional tool to identify patients at high
cardiometabolic risk. The term ‘‘metabolic syndrome’’ refers
to a clustering of specific cardiovascular disease (CVD) risk
factors whose underlying pathophysiology is believed to be
related to insulin resistance. It has been postulated that
insulin resistance and its compensatory hyperinsulinemia
predisposes patients to hypertension, hyperlipidaemia, dia-
betes, and obesity [14]. The available definitions of the
metabolic syndrome for diagnostic purposes need for further
harmonisation, as different organisations have developed
similar but not identical criteria, excluding other risk factors
such as age and history of CVD events. Current definitions of
the syndrome capture people with diagnosed disease (e.g.
diabetes, hypertension, clinical CVD), as well as those who
have milder and ‘‘normal’’ conditions. Although some
authors stated that in the near future new definition(s) will be
applicable worldwide [15], others suggested that this
expansion in prevalence estimates exploits the widespread
profitable short- and long-term use of rimonabant, creating a
new market [16].
In light of these considerations, it should be assessed if
and how the management of the metabolic syndrome as a
whole would differ from the treatment of the individual
components. There is no question that the risk factors for
cardiovascular disease cluster together. The question is
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whether the cluster of features conceals a distinct clinical
entity. In other words, it is far to be fully demonstrated that
the whole is greater than the sum of the parts. In the near
future, the risk would be that rimonabant will be proposed
to any one individual overweight or with just a threat of
cardiovascular symptoms. A broad population, with the
largest majority of subject at low-baseline risk of disease,
will be exposed to medicalization and adverse events
without knowing the real benefits deriving from this
treatment [17]. The outcome being probabilistic, CVD
events will not be prevented because they will never
develop. For a public health system the related costs will be
difficult to absorb. This strategy has been defined as disease
mongering, i.e. the selling of sickness that widens the
boundaries of illness and grows the markets for those who
sell and deliver treatments. [18] We invite readers to take a
careful look at a recent special issue of PLoS Medicine—a
leading open access journal—to have a proper under-
standing of this phenomenon [17–19].
The ‘‘rimonabant regulatory case’’ constitutes a very
important precedent in the field of cardiovascular drugs.
Naming a syndrome does not automatically mean that it
exists. In the field of cardiovascular risk factors the
temptation to enlarge the ‘‘abnormal’’ population and,
subsequently, the market of treatment is very high. An
‘‘universal’’ indication as ‘‘Management of multiple car-
diovascular risk factors in patients with metabolic
syndrome’’, which will expose millions of patients to a
drug therapy, cannot be granted on the basis of the very
limited knowledge of the metabolic syndrome available to
date. Furthermore, assuming the validity of the metabolic
syndrome definition, the lack of comparative data with the
existing cardiovascular risk factor treatments (statins,
antihypertensive agents, hypoglicaemic agents, physical
exercise, etc.) precludes any attempt to find rimonabant a
‘‘place in therapy’’. It should be underlined that new clin-
ical and therapeutical options should address relevant
public health needs rather than market-driven pseudo-
needs. To set new drug indications into a more relevant
scenario, clinicians, reviewers and regulatory agencies
should always consider to base their evaluation on the body
of evidence already available, being resistant to market
drift.
A clinician’s point of view
Gian Franco Gensini  Roberto Gusinu 
Andrea A. Conti
In the past few years the popularity of the ‘‘metabolic
syndrome’’ has become more and more diffused, parallel-
ing the increasing discussion relative to its epidemiological
definition, pathophysiological meaning, and clinical rele-
vance. The metabolic syndrome is an articulated clinical
complex interpreted as a clustering of risk factors associ-
ated with an increased risk in cardiovascular diseases and
mortality and in diabetes mellitus. In some studies, its
prevalence in the USA has been computed as being even
more than 25% in the population [20].
On diagnostic grounds, various definitions for the
‘‘metabolic syndrome’’ have been proposed through time;
in 1999, for example, the World Health Organization stated
that, to make the diagnosis of this syndrome, a patient
should present with impaired glucose tolerance, impaired
fasting glucose, insulin resistance or diabetes mellitus, plus
two or more of the following elements: arterial hyperten-
sion, central obesity, increased plasma triglycerides and/or
low HDL cholesterol, microalbuminuria [21].
According to the new International Diabetes Federation
definition (2005), central obesity has become the pivotal
factor, and to perform the diagnosis, obesity must be
accompanied by at least two of the following four ele-
ments: reduced HDL cholesterol or specific therapy for this
disorder, increased triglycerides values or specific therapy
for this disorder, arterial hypertension or therapy of pre-
viously diagnosed hypertension, raised fasting plasma
glucose or previously diagnosed type 2 diabetes mellitus
[21].
The different definitions available on the one hand
indicate that a general consensus on the ‘‘metabolic syn-
drome’’ seems to have been not yet achieved, and, on the
other, point to the fact that, in any case, the therapeutic
management of this syndrome should be harmonic and
integrated.
Rimonabant has only one therapeutic target (body
weight) and therefore, from a theoretical point of view,
only concentrates on a specific element, and not on the
whole complex clinical entity called ‘‘metabolic syn-
drome’’. From an operational standpoint, indirect
comparisons with other approved drugs for obesity, such as
sibutramine and orlistat, show that the weight loss associ-
ated with rimonabant overlaps that with sibutramine and it
is slightly higher than that with orlistat. Considering also
the depressive symptoms and mood disorders reported by
patients on rimonabant in clinical trials (as indicated in the
meta-analysis by Christensen et al. [22]), the efficacy and
safety profiles of this drug consequently need further
structured systematic evaluation.
This appears particularly relevant today, in an era of
evidence-based medicine, so as to vigorously prevent and
reduce the so-called ‘‘disease mongering’’ phenomenon
[23]. Since various clinical elements associate in a syner-
gic negative congregation in subjects at increased risk
of cardiovascular disease, evidence-based therapeutic
interventions should contemporaneously target different
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features, having clearly demonstrated their efficacy and
safety on the combination of the different elements of the
so-called ‘‘metabolic syndrome’’, and therefore on the
patient/person as a whole.
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